MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cell Ročník 151; číslo 5; s. 937
Hlavní autori: Huang, Sidong, Hölzel, Michael, Knijnenburg, Theo, Schlicker, Andreas, Roepman, Paul, McDermott, Ultan, Garnett, Mathew, Grernrum, Wipawadee, Sun, Chong, Prahallad, Anirudh, Groenendijk, Floris H, Mittempergher, Lorenza, Nijkamp, Wouter, Neefjes, Jacques, Salazar, Ramon, Ten Dijke, Peter, Uramoto, Hidetaka, Tanaka, Fumihiro, Beijersbergen, Roderick L, Wessels, Lodewyk F A, Bernards, René
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 21.11.2012
Predmet:
ISSN:1097-4172, 1097-4172
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGF-βR2 through physical interaction. MED12 suppression therefore results in activation of TGF-βR signaling, which is both necessary and sufficient for drug resistance. TGF-β signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-βR signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
AbstractList Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGF-βR2 through physical interaction. MED12 suppression therefore results in activation of TGF-βR signaling, which is both necessary and sufficient for drug resistance. TGF-β signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-βR signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGF-βR2 through physical interaction. MED12 suppression therefore results in activation of TGF-βR signaling, which is both necessary and sufficient for drug resistance. TGF-β signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-βR signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGF-βR2 through physical interaction. MED12 suppression therefore results in activation of TGF-βR signaling, which is both necessary and sufficient for drug resistance. TGF-β signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-βR signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
Author Hölzel, Michael
Sun, Chong
Huang, Sidong
Neefjes, Jacques
Ten Dijke, Peter
Groenendijk, Floris H
Bernards, René
Wessels, Lodewyk F A
Knijnenburg, Theo
Nijkamp, Wouter
Schlicker, Andreas
Roepman, Paul
McDermott, Ultan
Salazar, Ramon
Tanaka, Fumihiro
Grernrum, Wipawadee
Prahallad, Anirudh
Uramoto, Hidetaka
Garnett, Mathew
Mittempergher, Lorenza
Beijersbergen, Roderick L
Author_xml – sequence: 1
  givenname: Sidong
  surname: Huang
  fullname: Huang, Sidong
  organization: Division of Molecular Carcinogenesis, Cancer Genomics Center and Cancer Systems Biology Center, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
– sequence: 2
  givenname: Michael
  surname: Hölzel
  fullname: Hölzel, Michael
– sequence: 3
  givenname: Theo
  surname: Knijnenburg
  fullname: Knijnenburg, Theo
– sequence: 4
  givenname: Andreas
  surname: Schlicker
  fullname: Schlicker, Andreas
– sequence: 5
  givenname: Paul
  surname: Roepman
  fullname: Roepman, Paul
– sequence: 6
  givenname: Ultan
  surname: McDermott
  fullname: McDermott, Ultan
– sequence: 7
  givenname: Mathew
  surname: Garnett
  fullname: Garnett, Mathew
– sequence: 8
  givenname: Wipawadee
  surname: Grernrum
  fullname: Grernrum, Wipawadee
– sequence: 9
  givenname: Chong
  surname: Sun
  fullname: Sun, Chong
– sequence: 10
  givenname: Anirudh
  surname: Prahallad
  fullname: Prahallad, Anirudh
– sequence: 11
  givenname: Floris H
  surname: Groenendijk
  fullname: Groenendijk, Floris H
– sequence: 12
  givenname: Lorenza
  surname: Mittempergher
  fullname: Mittempergher, Lorenza
– sequence: 13
  givenname: Wouter
  surname: Nijkamp
  fullname: Nijkamp, Wouter
– sequence: 14
  givenname: Jacques
  surname: Neefjes
  fullname: Neefjes, Jacques
– sequence: 15
  givenname: Ramon
  surname: Salazar
  fullname: Salazar, Ramon
– sequence: 16
  givenname: Peter
  surname: Ten Dijke
  fullname: Ten Dijke, Peter
– sequence: 17
  givenname: Hidetaka
  surname: Uramoto
  fullname: Uramoto, Hidetaka
– sequence: 18
  givenname: Fumihiro
  surname: Tanaka
  fullname: Tanaka, Fumihiro
– sequence: 19
  givenname: Roderick L
  surname: Beijersbergen
  fullname: Beijersbergen, Roderick L
– sequence: 20
  givenname: Lodewyk F A
  surname: Wessels
  fullname: Wessels, Lodewyk F A
– sequence: 21
  givenname: René
  surname: Bernards
  fullname: Bernards, René
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23178117$$D View this record in MEDLINE/PubMed
BookMark eNpNkLtOwzAARS1URB_wAwzII0uCH3HjjKi0BamIpcyR7ThpKscOtjPwW3wI30QqisR0r66O7nDmYGKd1QDcYpRihJcPx1RpY1KCMBmHFFF2AWYYFXmS4ZxM_vUpmIdwRAhxxtgVmBKKc45xPgPV6_oJE6icjd6ZAONBQ69D72zQMDrYDSa2vdFQCau0h5UfmhPl3dAcRrIZjIits9DVcL_dJN9f46h0H52HoW2sMK1trsFlLUzQN-dcgPfNer96TnZv25fV4y5RDJOYcJwXVJKKC15LhAvGKZcMFQzXBcKcKsGELpiUstA8G3PJRV1JIQqiFCGULMD972_v3cegQyy7NpwcCavdEEpMCKJLmmVsRO_O6CA7XZW9bzvhP8s_M-QHAHFpbA
CitedBy_id crossref_primary_10_1074_jbc_RA118_001725
crossref_primary_10_1210_endocr_bqae114
crossref_primary_10_1016_j_gde_2019_03_003
crossref_primary_10_1002_pros_23092
crossref_primary_10_1097_PAS_0000000000001207
crossref_primary_10_1007_s13238_014_0076_6
crossref_primary_10_1016_j_ebiom_2019_11_011
crossref_primary_10_1016_j_molcel_2015_08_013
crossref_primary_10_3390_cells8080821
crossref_primary_10_1016_j_gpb_2013_05_002
crossref_primary_10_1016_j_canlet_2024_217220
crossref_primary_10_1038_cddis_2014_554
crossref_primary_10_1371_journal_pone_0130826
crossref_primary_10_1016_j_tig_2015_11_003
crossref_primary_10_1111_febs_17225
crossref_primary_10_1158_0008_5472_CAN_21_1415
crossref_primary_10_1007_s00018_025_05791_w
crossref_primary_10_1111_bjd_20760
crossref_primary_10_7554_eLife_65150
crossref_primary_10_1038_cr_2015_16
crossref_primary_10_1158_1078_0432_CCR_21_3750
crossref_primary_10_1002_wsbm_1511
crossref_primary_10_1097_GCO_0000000000000185
crossref_primary_10_15252_embj_2021108791
crossref_primary_10_1177_1758835919890286
crossref_primary_10_7554_eLife_91316_3
crossref_primary_10_3389_fonc_2015_00031
crossref_primary_10_1002_ijc_28782
crossref_primary_10_3389_fimmu_2025_1571731
crossref_primary_10_1016_j_bbagen_2014_02_004
crossref_primary_10_1016_j_molcel_2017_12_016
crossref_primary_10_1007_s13238_013_3048_3
crossref_primary_10_1016_j_gde_2013_11_007
crossref_primary_10_1158_1078_0432_CCR_18_4145
crossref_primary_10_1007_s10585_021_10077_z
crossref_primary_10_1016_j_devcel_2021_02_028
crossref_primary_10_1016_j_cell_2012_11_003
crossref_primary_10_1016_j_drup_2018_01_001
crossref_primary_10_1016_j_jid_2020_07_024
crossref_primary_10_1517_17460441_2013_843523
crossref_primary_10_2174_1381612825666191105114539
crossref_primary_10_1101_gr_144774_112
crossref_primary_10_1158_0008_5472_CAN_20_1810
crossref_primary_10_1038_cr_2015_23
crossref_primary_10_3892_ol_2020_11483
crossref_primary_10_1038_s41388_018_0378_x
crossref_primary_10_1002_med_21338
crossref_primary_10_1210_endocr_bqab186
crossref_primary_10_1094_PHYTO_12_21_0495_R
crossref_primary_10_1016_j_molonc_2015_02_008
crossref_primary_10_3389_fonc_2014_00190
crossref_primary_10_1016_j_coph_2013_06_004
crossref_primary_10_3390_cancers12061475
crossref_primary_10_3389_fimmu_2024_1348189
crossref_primary_10_1016_j_molcel_2013_04_029
crossref_primary_10_1038_s41392_020_00436_9
crossref_primary_10_1038_ng_2515
crossref_primary_10_1101_gad_319194_118
crossref_primary_10_1093_g3journal_jkaa069
crossref_primary_10_1684_bdc_2013_1691
crossref_primary_10_1371_journal_pgen_1007935
crossref_primary_10_1158_0008_5472_CAN_14_1174
crossref_primary_10_1186_1475_2867_14_18
crossref_primary_10_3389_fphar_2020_566401
crossref_primary_10_3390_cells8121481
crossref_primary_10_1038_s41523_021_00248_2
crossref_primary_10_4161_15384101_2014_988033
crossref_primary_10_1007_s11033_019_04958_6
crossref_primary_10_1515_hsz_2017_0304
crossref_primary_10_1007_s43440_024_00589_2
crossref_primary_10_1038_nature13121
crossref_primary_10_1016_j_fertnstert_2021_05_081
crossref_primary_10_1016_j_devcel_2024_12_035
crossref_primary_10_1016_j_molcel_2018_03_006
crossref_primary_10_1016_j_tvjl_2015_06_015
crossref_primary_10_1146_annurev_pathol_012615_044438
crossref_primary_10_1158_1078_0432_CCR_13_1943
crossref_primary_10_1056_NEJMra1209993
crossref_primary_10_3892_ijo_2023_5575
crossref_primary_10_1038_s41416_021_01519_2
crossref_primary_10_1016_S0140_6736_13_61715_8
crossref_primary_10_1007_s00204_015_1472_2
crossref_primary_10_1016_j_pharmthera_2017_11_004
crossref_primary_10_1136_gutjnl_2016_313334
crossref_primary_10_1002_ajh_24301
crossref_primary_10_1016_j_steroids_2017_11_007
crossref_primary_10_1016_j_isci_2023_106914
crossref_primary_10_1038_s41416_024_02642_6
crossref_primary_10_1016_j_tibs_2013_10_001
crossref_primary_10_1093_humupd_dmv030
crossref_primary_10_1111_jcmm_17211
crossref_primary_10_1111_imr_12789
crossref_primary_10_1158_1078_0432_CCR_24_0468
crossref_primary_10_1016_j_bbcan_2013_12_001
crossref_primary_10_1080_14789450_2017_1299006
crossref_primary_10_1038_nmeth_2436
crossref_primary_10_1002_ijc_33003
crossref_primary_10_1089_thy_2022_0428
crossref_primary_10_1093_nar_gkab540
crossref_primary_10_3390_ijms24021601
crossref_primary_10_1158_0008_5472_CAN_23_1749
crossref_primary_10_1007_s12282_017_0821_9
crossref_primary_10_1152_physrev_00010_2024
crossref_primary_10_1038_oncsis_2016_33
crossref_primary_10_1158_0008_5472_CAN_15_1326
crossref_primary_10_1016_j_scib_2018_09_024
crossref_primary_10_1515_jbcpp_2019_0119
crossref_primary_10_1038_s41698_023_00486_6
crossref_primary_10_1038_nm_3388
crossref_primary_10_1038_nrc3599
crossref_primary_10_1038_s41598_025_95250_0
crossref_primary_10_1073_pnas_1917635117
crossref_primary_10_1007_s00535_014_0943_1
crossref_primary_10_1016_j_cell_2018_04_012
crossref_primary_10_1371_journal_pone_0104998
crossref_primary_10_1111_cas_13185
crossref_primary_10_1158_2159_8290_CD_18_0469
crossref_primary_10_1038_onc_2016_348
crossref_primary_10_1097_JTO_0000000000000170
crossref_primary_10_1016_j_ejmg_2017_06_004
crossref_primary_10_3390_cancers14061561
crossref_primary_10_3390_ijms18112435
crossref_primary_10_1007_s11845_025_04029_9
crossref_primary_10_1056_NEJMcibr1214549
crossref_primary_10_1186_s12885_019_5650_0
crossref_primary_10_1158_0008_5472_CAN_14_0839
crossref_primary_10_3390_ijms22062911
crossref_primary_10_1002_advs_202402327
crossref_primary_10_1038_nm_3930
crossref_primary_10_1016_j_semradonc_2014_12_007
crossref_primary_10_15252_emmm_201606184
crossref_primary_10_4251_wjgo_v13_i11_1648
crossref_primary_10_1016_j_bbrc_2023_04_053
crossref_primary_10_3390_biom12121880
crossref_primary_10_1210_endrev_bnab039
crossref_primary_10_3892_ol_2024_14531
crossref_primary_10_3390_ph17040533
crossref_primary_10_1074_jbc_M116_713735
crossref_primary_10_1038_nrc3498
crossref_primary_10_3390_cancers14246101
crossref_primary_10_1007_s00018_021_04056_6
crossref_primary_10_3390_genes13040692
crossref_primary_10_3389_fimmu_2025_1653794
crossref_primary_10_1016_j_sbi_2016_07_019
crossref_primary_10_1002_gcc_22256
crossref_primary_10_1530_REP_13_0580
crossref_primary_10_1016_j_carbon_2017_05_084
crossref_primary_10_1186_s12920_018_0449_4
crossref_primary_10_1158_0008_5472_CAN_18_2052
crossref_primary_10_1038_nrm3951
crossref_primary_10_1016_j_semcancer_2023_10_003
crossref_primary_10_1038_srep35483
crossref_primary_10_1016_j_resinv_2018_09_001
crossref_primary_10_1093_nar_gkz122
crossref_primary_10_1155_2018_9732939
crossref_primary_10_1158_0008_5472_CAN_13_0512
crossref_primary_10_1093_nar_gkw1093
crossref_primary_10_1371_journal_pone_0078086
crossref_primary_10_1016_j_tranon_2018_11_014
crossref_primary_10_1158_0008_5472_CAN_15_1113
crossref_primary_10_1016_j_ccell_2015_02_005
crossref_primary_10_1038_s41388_020_1299_z
crossref_primary_10_1371_journal_pone_0103050
crossref_primary_10_1097_MD_0000000000009636
crossref_primary_10_1158_1078_0432_CCR_15_2996
crossref_primary_10_1016_j_cmet_2015_08_007
crossref_primary_10_1038_cddis_2016_328
crossref_primary_10_1016_j_cell_2016_02_059
crossref_primary_10_1016_j_compbiomed_2024_108703
crossref_primary_10_1093_abbs_gmx123
crossref_primary_10_1002_ggn2_202200014
crossref_primary_10_1186_2049_3002_2_20
crossref_primary_10_1007_s00210_025_04006_0
crossref_primary_10_1158_2159_8290_CD_13_0741
crossref_primary_10_1016_j_ijrobp_2014_09_026
crossref_primary_10_1007_s12013_021_00980_3
crossref_primary_10_1016_j_molonc_2014_05_004
crossref_primary_10_1038_s42003_021_02481_8
crossref_primary_10_1016_j_biomaterials_2018_01_023
crossref_primary_10_2478_ast_2020_0005
crossref_primary_10_1111_jcmm_13229
crossref_primary_10_1016_j_ejmech_2021_113660
crossref_primary_10_1002_jcp_30099
crossref_primary_10_1038_s41571_019_0222_4
crossref_primary_10_1016_j_tibs_2022_01_002
crossref_primary_10_1016_j_ydbio_2013_10_023
crossref_primary_10_1089_gtmb_2014_0273
crossref_primary_10_1371_journal_pgen_1009176
crossref_primary_10_1093_nar_gkt641
crossref_primary_10_1586_era_12_170
crossref_primary_10_1016_j_jconrel_2020_10_031
crossref_primary_10_1038_onc_2016_426
crossref_primary_10_1016_j_jvir_2013_03_034
crossref_primary_10_1038_s41467_024_49673_4
crossref_primary_10_1124_molpharm_123_000776
crossref_primary_10_1038_bjc_2015_146
crossref_primary_10_1111_cas_16250
crossref_primary_10_1016_j_stem_2013_04_013
crossref_primary_10_1016_j_fertnstert_2020_07_049
crossref_primary_10_1038_s41467_018_04999_8
crossref_primary_10_1038_ncomms3467
crossref_primary_10_1089_gtmb_2023_0641
crossref_primary_10_1210_jc_2015_3555
crossref_primary_10_1111_febs_13248
crossref_primary_10_1093_nar_gkab1184
crossref_primary_10_1158_0008_5472_CAN_13_1755
crossref_primary_10_1186_s12885_017_3249_x
crossref_primary_10_1016_j_ctrv_2014_05_009
crossref_primary_10_1158_0008_5472_CAN_23_1127
crossref_primary_10_1016_j_ab_2016_05_014
crossref_primary_10_1016_j_bbcan_2025_189442
crossref_primary_10_1016_j_drup_2016_07_001
crossref_primary_10_1016_j_ydbio_2016_06_009
crossref_primary_10_1038_s41571_020_0403_1
crossref_primary_10_1038_celldisc_2016_31
crossref_primary_10_1111_bjh_20028
crossref_primary_10_1126_sciadv_1500463
crossref_primary_10_1007_s10120_014_0444_1
crossref_primary_10_1186_s12885_021_08419_x
crossref_primary_10_1016_j_molcel_2013_10_004
crossref_primary_10_1164_rccm_201304_0716UP
crossref_primary_10_3389_fmed_2017_00030
crossref_primary_10_1158_0008_5472_CAN_17_2834
crossref_primary_10_1038_cdd_2017_9
crossref_primary_10_1080_21541264_2018_1556915
crossref_primary_10_3390_ijms24043742
crossref_primary_10_1002_1878_0261_13357
crossref_primary_10_1038_nm_3679
crossref_primary_10_1016_j_cels_2016_09_001
crossref_primary_10_1038_s41467_022_35134_3
crossref_primary_10_1016_j_drup_2020_100715
crossref_primary_10_1002_humu_23157
crossref_primary_10_3390_ijms25021307
crossref_primary_10_3892_ijmm_2015_2268
crossref_primary_10_1038_clpt_2012_237
crossref_primary_10_1038_s41418_019_0455_x
crossref_primary_10_1016_j_ejca_2015_04_023
crossref_primary_10_1016_j_stem_2019_03_022
crossref_primary_10_1159_000528539
crossref_primary_10_1016_j_bcp_2013_01_018
crossref_primary_10_1155_2019_3851576
crossref_primary_10_3390_biomedicines7030065
crossref_primary_10_1016_j_drup_2015_12_001
crossref_primary_10_1016_j_jaci_2017_07_019
crossref_primary_10_1136_gutjnl_2019_318506
crossref_primary_10_1016_j_bbamcr_2015_05_035
crossref_primary_10_1186_s13578_017_0168_0
crossref_primary_10_1016_j_bbrc_2022_04_029
crossref_primary_10_1371_journal_ppat_1004143
crossref_primary_10_1126_science_1247005
crossref_primary_10_3109_10409238_2013_840259
crossref_primary_10_1038_s41467_017_02584_z
crossref_primary_10_1016_j_semcancer_2016_08_009
crossref_primary_10_1073_pnas_1500223112
crossref_primary_10_26508_lsa_201800117
crossref_primary_10_1073_pnas_1608319113
crossref_primary_10_1038_ncomms15021
crossref_primary_10_3892_ijo_2014_2623
crossref_primary_10_1080_08977194_2025_2516463
crossref_primary_10_1158_0008_5472_CAN_18_0134
crossref_primary_10_3892_ol_2022_13194
crossref_primary_10_2217_lmt_13_63
crossref_primary_10_1016_j_canlet_2015_08_003
crossref_primary_10_1007_s12032_023_02259_4
crossref_primary_10_3109_1547691X_2014_945667
crossref_primary_10_1002_ijc_35035
crossref_primary_10_1158_1078_0432_CCR_15_0143
crossref_primary_10_1111_febs_17097
crossref_primary_10_3389_fphar_2014_00252
crossref_primary_10_3390_cancers14122928
crossref_primary_10_1016_j_resinv_2014_10_002
crossref_primary_10_3390_ijms252413418
crossref_primary_10_1002_ijc_29723
crossref_primary_10_1038_nrc3423
crossref_primary_10_1038_s41388_018_0606_4
crossref_primary_10_1016_j_semcancer_2014_05_006
crossref_primary_10_1093_nar_gkv037
crossref_primary_10_1039_C9NR09585C
crossref_primary_10_1016_j_ccr_2014_03_010
crossref_primary_10_1038_s41467_018_06958_9
crossref_primary_10_1016_j_biopha_2019_108708
crossref_primary_10_1074_jbc_RA119_012404
crossref_primary_10_1016_j_cell_2015_02_038
crossref_primary_10_1186_s40001_022_00856_z
crossref_primary_10_7554_eLife_91316
crossref_primary_10_1038_s41388_018_0655_8
crossref_primary_10_1016_j_gim_2024_101222
crossref_primary_10_1016_j_tcb_2017_07_001
crossref_primary_10_1038_491641c
crossref_primary_10_1002_cncr_32672
crossref_primary_10_1177_1753465815587820
crossref_primary_10_3389_fcell_2021_786728
crossref_primary_10_1002_1878_0261_13545
crossref_primary_10_1007_s13402_014_0210_8
crossref_primary_10_1146_annurev_cancerbio_070620_103554
crossref_primary_10_1016_j_celrep_2024_114224
crossref_primary_10_1038_s41392_024_02075_w
crossref_primary_10_1016_j_ejmech_2021_113763
crossref_primary_10_1371_journal_pone_0134682
crossref_primary_10_1016_j_critrevonc_2015_08_004
crossref_primary_10_1016_j_canlet_2016_01_037
crossref_primary_10_1080_17476348_2019_1656068
crossref_primary_10_1158_1541_7786_MCR_15_0291_T
crossref_primary_10_1002_advs_201700964
crossref_primary_10_1038_onc_2013_588
crossref_primary_10_1177_15330338211068965
crossref_primary_10_4161_cc_26034
crossref_primary_10_1155_2016_4684268
crossref_primary_10_3389_fonc_2020_01184
crossref_primary_10_3748_wjg_v29_i13_1911
crossref_primary_10_1016_j_prp_2025_155838
crossref_primary_10_1158_0008_5472_CAN_12_4502
crossref_primary_10_1038_s41467_021_25260_9
crossref_primary_10_1007_s11684_018_0646_8
ContentType Journal Article
Copyright Copyright © 2012 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2012 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.cell.2012.10.035
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1097-4172
ExternalDocumentID 23178117
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Wellcome Trust
  grantid: 093868
GroupedDBID ---
--K
-DZ
-ET
-~X
0R~
0WA
1RT
1~5
29B
2FS
2WC
3EH
4.4
457
4G.
53G
5GY
5RE
5VS
62-
6J9
7-5
85S
9M8
AAEDT
AAEDW
AAFWJ
AAHBH
AAIKJ
AAKRW
AAKUH
AALRI
AAMRU
AAQFI
AAVLU
AAXUO
AAYJJ
AAYWO
ABCQX
ABDGV
ABJNI
ABMAC
ABOCM
ACGFO
ACGFS
ACNCT
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
ADXHL
AEFWE
AENEX
AEUPX
AEXQZ
AFPUW
AFTJW
AGCQF
AGHFR
AGHSJ
AGKMS
AHHHB
AIDAL
AIGII
AITUG
AKAPO
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
F5P
FCP
FDB
FIRID
HH5
HZ~
IH2
IHE
IXB
J1W
JIG
K-O
KOO
KQ8
L7B
LX5
M3Z
M41
N9A
NPM
O-L
O9-
OK1
P2P
RIG
RNS
ROL
RPZ
SCP
SDG
SDP
SES
SSZ
TAE
TN5
TR2
TWZ
UKR
UPT
WH7
YYQ
YZZ
ZCA
ZY4
7X8
ID FETCH-LOGICAL-c512t-81793b2d8a8fb0195838b50951f90183ca5ae95bbb9e845bb68afdbaa92cc2232
IEDL.DBID 7X8
ISICitedReferencesCount 368
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000311423500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1097-4172
IngestDate Sun Sep 28 01:14:32 EDT 2025
Mon Jul 21 05:29:22 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright © 2012 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c512t-81793b2d8a8fb0195838b50951f90183ca5ae95bbb9e845bb68afdbaa92cc2232
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.cell.com/article/S0092867412012962/pdf
PMID 23178117
PQID 1220363445
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1220363445
pubmed_primary_23178117
PublicationCentury 2000
PublicationDate 2012-11-21
PublicationDateYYYYMMDD 2012-11-21
PublicationDate_xml – month: 11
  year: 2012
  text: 2012-11-21
  day: 21
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cell
PublicationTitleAlternate Cell
PublicationYear 2012
References 23178113 - Cell. 2012 Nov 21;151(5):927-9. doi: 10.1016/j.cell.2012.11.003.
23222482 - Nat Rev Cancer. 2013 Jan;13(1):6-7. doi: 10.1038/nrc3423.
References_xml – reference: 23222482 - Nat Rev Cancer. 2013 Jan;13(1):6-7. doi: 10.1038/nrc3423.
– reference: 23178113 - Cell. 2012 Nov 21;151(5):927-9. doi: 10.1016/j.cell.2012.11.003.
SSID ssj0008555
Score 2.5679436
Snippet Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 937
SubjectTerms Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
Humans
Lung Neoplasms - drug therapy
MAP Kinase Signaling System
Mediator Complex - genetics
Mediator Complex - metabolism
Neoplasms - drug therapy
Receptors, Transforming Growth Factor beta - metabolism
Signal Transduction
Title MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling
URI https://www.ncbi.nlm.nih.gov/pubmed/23178117
https://www.proquest.com/docview/1220363445
Volume 151
WOSCitedRecordID wos000311423500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAgsSFfSmbjMTV0Dhx6pwQghYOtOqhSL1F3lJxSUrSIvFbfAjfxEziigsHJC6JFNlS5Bl7nu038wi5Co1yFjbKmH7WYRChBJMusAx2YTwUKtZS19X1n7vDoZxMkpE_cKs8rXK5JtYLtS0MnpHfBByvzMIoErezN4aqUXi76iU0VkkrBCiDXt2d_FQLl6JWPcVLVhZBpPZJMw2_Cw_GkdrFr5Hd5eXefoWYdajpb__3J3fIlgeZ9K7xil2y4vI9stHITn7sEzvoPQScepZ6RQED0rLhyjo6L-iSZEgNukRJbbmYYqta0QdaTr3kFy0yOn7ss69P-Ij0mKKkyAdRmOJ-QF76vfH9E_NqC8xA0J8ziVNVcyuVzDSmEcpQaoEILAPMIMGoQrlEaK0TJyN4x1JlViuVcGPAsPyQrOVF7o4JjaOuVsa4BOuxJaqjQ6m0E1Fs4yixcdwml8vhS8Gb0RIqd8WiSn8GsE2OGhuks6bsRgpItE6LPflD71OyiabFpEEenJFWBnPZnZN18z5_rcqL2k3gORwNvgEddceN
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MED12+controls+the+response+to+multiple+cancer+drugs+through+regulation+of+TGF-%CE%B2+receptor+signaling&rft.jtitle=Cell&rft.au=Huang%2C+Sidong&rft.au=H%C3%B6lzel%2C+Michael&rft.au=Knijnenburg%2C+Theo&rft.au=Schlicker%2C+Andreas&rft.date=2012-11-21&rft.issn=1097-4172&rft.eissn=1097-4172&rft.volume=151&rft.issue=5&rft.spage=937&rft_id=info:doi/10.1016%2Fj.cell.2012.10.035&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1097-4172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1097-4172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1097-4172&client=summon